Schneider-Hohendorf Tilman, Philipp Konstanze, Husstedt Ingo W, Wiendl Heinz, Schwab Nicholas
Department of Neurology, University of Münster, Münster, Germany.
AIDS. 2014 Mar 13;28(5):793-5. doi: 10.1097/QAD.0000000000000201.
HIV(+) progressive multifocal leukoencephalopathy (PML) patients had a significantly lower expression of CD62L on CD4(+) T cells (P < 0.001) when compared with HIV(+) patients who did not develop PML. CD62L expression on CD4(+) T cells did not correlate with parameters such as CDC stage, CD4(+) cell percentage (of total CD3(+) T cells), CD4(+) cell counts, virus count, or clinical parameters. Measurement of CD62L might provide a biomarker for PML risk and could prompt a treatment change and/or close monitoring.
与未发生进行性多灶性白质脑病（PML）的HIV阳性患者相比，HIV阳性的PML患者CD4(+) T细胞上CD62L的表达显著降低（P < 0.001）。CD4(+) T细胞上CD62L的表达与诸如疾病控制中心（CDC）分期、CD4(+)细胞百分比（占总CD3(+) T细胞的比例）、CD4(+)细胞计数、病毒载量或临床参数等指标无关。CD62L的检测可能为PML风险提供一种生物标志物，并可能促使治疗方案的改变和/或密切监测。
